[go: up one dir, main page]

AR105238A1 - Compuestos de benzoxacepina oxazolidinona y métodos de uso - Google Patents

Compuestos de benzoxacepina oxazolidinona y métodos de uso

Info

Publication number
AR105238A1
AR105238A1 ARP160102006A ARP160102006A AR105238A1 AR 105238 A1 AR105238 A1 AR 105238A1 AR P160102006 A ARP160102006 A AR P160102006A AR P160102006 A ARP160102006 A AR P160102006A AR 105238 A1 AR105238 A1 AR 105238A1
Authority
AR
Argentina
Prior art keywords
benzoxacepin
methods
oxazolidinone compounds
oxazolidinone
compounds
Prior art date
Application number
ARP160102006A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR105238A1 publication Critical patent/AR105238A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un compuesto seleccionado entre la fórmula (1), y estereoisómeros, isómeros geométricos, tautómeros, y sales farmacéuticamente aceptables de los mismos, en donde: R¹ se selecciona entre -CH₃, -CH₂CH₃, ciclopropilo, y ciclobutilo; R² se selecciona entre -CH₃, -CHF₂, -CH₂F, y -CF₃.
ARP160102006A 2015-07-02 2016-07-01 Compuestos de benzoxacepina oxazolidinona y métodos de uso AR105238A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562188029P 2015-07-02 2015-07-02

Publications (1)

Publication Number Publication Date
AR105238A1 true AR105238A1 (es) 2017-09-20

Family

ID=56292756

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102006A AR105238A1 (es) 2015-07-02 2016-07-01 Compuestos de benzoxacepina oxazolidinona y métodos de uso

Country Status (36)

Country Link
US (8) US9650393B2 (es)
EP (5) EP4585597A1 (es)
JP (4) JP6523490B2 (es)
KR (2) KR102014326B1 (es)
CN (4) CN111909173B (es)
AR (1) AR105238A1 (es)
AU (2) AU2016287463B2 (es)
CA (1) CA2982708C (es)
CL (1) CL2017003436A1 (es)
CO (1) CO2017011038A2 (es)
CR (1) CR20170563A (es)
DK (1) DK3317284T3 (es)
ES (2) ES2764497T3 (es)
FI (1) FIC20253008I1 (es)
FR (1) FR25C1039I1 (es)
HR (1) HRP20192349T1 (es)
HU (2) HUE046756T2 (es)
IL (3) IL255200B (es)
LT (2) LT3317284T (es)
MA (3) MA42295B1 (es)
MX (2) MX388533B (es)
MY (1) MY195002A (es)
NL (1) NL301344I2 (es)
NO (1) NO2025044I1 (es)
PE (2) PE20181021A1 (es)
PH (2) PH12017502425A1 (es)
PL (2) PL3317284T3 (es)
PT (1) PT3317284T (es)
RS (1) RS59740B1 (es)
RU (1) RU2730529C2 (es)
SG (1) SG10201913980SA (es)
SI (1) SI3317284T1 (es)
TW (4) TWI649326B (es)
UA (1) UA121678C2 (es)
WO (1) WO2017001645A1 (es)
ZA (2) ZA201808370B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4585597A1 (en) * 2015-07-02 2025-07-16 F. Hoffmann-La Roche AG Benzoxazepin oxazolidinone compounds and methods of use
CN111848643A (zh) 2015-07-02 2020-10-30 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
JP6785252B2 (ja) 2015-07-02 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二環式ラクタム及びその使用方法
WO2017042182A1 (en) 2015-09-08 2017-03-16 F. Hoffmann-La Roche Ag Tricyclic pi3k inhibitor compounds and methods of use
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
JP7349359B2 (ja) 2016-10-17 2023-09-22 エフ． ホフマン－ラ ロシュ アーゲー 二環式ピリドンラクタム及びその使用方法。
EP3851441B1 (en) * 2016-12-15 2023-06-28 F. Hoffmann-La Roche AG Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
WO2018197653A1 (en) * 2017-04-28 2018-11-01 F. Hoffmann-La Roche Ag Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
WO2019204537A1 (en) 2018-04-20 2019-10-24 Genentech, Inc. N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
CA3101227A1 (en) * 2018-05-30 2019-12-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof
JP2021532139A (ja) * 2018-07-23 2021-11-25 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐｉ３ｋ阻害剤であるｇｄｃ−００７７による癌の治療方法
JP2022504388A (ja) 2018-10-08 2022-01-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｉ３ｋアルファ阻害剤およびメトホルミンを用いたがんの処置方法
CN109265408B (zh) * 2018-12-11 2020-09-01 上海皓元生物医药科技有限公司 二氟甲基取代噁烷-2-酮的合成方法
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CN111995541B (zh) * 2019-05-27 2025-05-06 君实润佳(上海)医药科技有限公司 含有稳定重同位素的酰胺官能团的化合物及其应用
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
WO2021088845A1 (zh) * 2019-11-04 2021-05-14 贝达药业股份有限公司 咪唑烷酮类化合物及其制备方法与应用
EP4067363A4 (en) * 2019-11-25 2023-12-27 Shanghai Hansoh Biomedical Co., Ltd. SALT OR CRYSTAL FORM HAVING THREE CONDENSED RINGS AND PHARMACEUTICAL COMPOSITION THEREOF
CN112830935B (zh) * 2019-11-25 2023-12-22 上海翰森生物医药科技有限公司 含三并环类衍生物自由碱的晶型及其药物组合物
TW202133857A (zh) * 2019-12-03 2021-09-16 美商建南德克公司 用於乳癌治療之組合療法
MX2023006793A (es) * 2020-12-11 2023-06-20 Genentech Inc Tratamientos conjuntos para tratamiento de cancer her2.
CN116867791B (zh) * 2021-01-29 2025-09-16 广州嘉越医药科技有限公司 三并环类化合物及其应用
TWI808648B (zh) 2021-02-16 2023-07-11 美商建南德克公司 使用包含gdc-9545及gdc-0077之組合療法治療乳癌
CA3218470A1 (en) 2021-05-13 2022-11-17 Betta Pharmaceuticals Co., Ltd. Polymorph of imidazolidinone compound, preparation method therefor and use thereof
IL308457A (en) 2021-05-28 2024-01-01 Genentech Inc A process for preparing benzoxazepine oxazolidinone compounds
WO2023002988A1 (ja) 2021-07-19 2023-01-26 京セラ株式会社 通信方法
JP2024533975A (ja) * 2021-08-09 2024-09-18 スコーピオン セラピューティクス インコーポレイテッド Ｐｉ３ｋアイソフォームアルファを阻害する化合物及びがんを処置するための方法
KR20240167654A (ko) 2022-04-06 2024-11-27 제넨테크, 인크. 암의 치료를 위한 gdc-6036 및 gdc-0077을 포함하는 병용 요법
CN117466913A (zh) * 2022-07-27 2024-01-30 南京明德新药研发有限公司 一种5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英化合物的晶型及其制备方法
CN120187416A (zh) 2022-11-11 2025-06-20 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
TW202440096A (zh) 2023-03-24 2024-10-16 美商亞文納營運公司 雌激素受體降解劑之給藥方案
WO2025036856A1 (en) 2023-08-11 2025-02-20 F. Hoffmann-La Roche Ag Pharmaceutical formulation comprising a coated tablet
WO2025122470A1 (en) 2023-12-04 2025-06-12 Genentech, Inc. Combination therapies for treatment of breast cancer
WO2025122745A1 (en) 2023-12-05 2025-06-12 Genentech, Inc. Combination therapies for treatment of her2 cancer
WO2025181153A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with pi3k alpha inhibitors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
ATE502941T1 (de) * 2000-04-25 2011-04-15 Icos Corp Hemmer der menschlichen phosphatidyl-inositol-3- kinase delta
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
DE602004020263D1 (de) * 2003-12-22 2009-05-07 Acadia Pharm Inc Amino-substituierte diaryläa,dücyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen
PT2612862T (pt) 2004-05-13 2016-12-15 Icos Corp Quinazolinonas como inibidores de fosfatidilinositol 3-quinase delta humana
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
CN101203519A (zh) 2005-05-04 2008-06-18 辉瑞有限公司 用于治疗癌症和病毒感染如丙型肝炎的用作Toll样受体调节剂的2－酰氨基－6－氨基－8－氧代嘌呤衍生物
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
CL2007001165A1 (es) 2006-04-26 2008-01-25 Hoffmann La Roche 2-(1h-indazol-4-il)-6-(4-metanosulfonil-piperazin-1-ilmetil)-4-morfolin-4-il-tieno[3,2-d]pirimidina; procedimiento de preparacion; composicion farmaceutica; proceso de preparacion de dicha composicion; kit farmaceutico; y uso para tratar enfermedades tales como cancer, desordenes inmunes y enfermedades cardiovasculares.
GB0610866D0 (en) 2006-06-02 2006-07-12 Hammersmith Imanet Ltd Novel in vivo imaging compounds
EA018573B1 (ru) 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
AR064155A1 (es) 2006-12-07 2009-03-18 Piramed Ltd Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso
KR20100097711A (ko) * 2007-11-21 2010-09-03 디코드 제네틱스 이에이치에프 폐 및 심혈관 질환의 치료를 위한 치환된 벤조아졸 ｐｄｅ4 억제제
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
SG10201407781SA (en) 2009-09-28 2015-01-29 Hoffmann La Roche Benzoxepin PI3K Inhibitor Compounds And Methods Of Use
SI2483278T1 (sl) 2009-09-28 2014-03-31 F. Hoffmann-La Roche Ag Inhibitorske spojine benzoksazepina pi3k in njihova uporaba pri zdravljenju raka
WO2011056930A2 (en) * 2009-11-06 2011-05-12 Emory University Fragile x mental retardation protein (fmrp), compositions, and methods related thereto
WO2012126901A1 (en) 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use
WO2013006532A1 (en) 2011-07-01 2013-01-10 Novartis Ag Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
NO3175985T3 (es) 2011-07-01 2018-04-28
UY34632A (es) * 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
MD20140100A2 (ro) 2012-03-05 2015-01-31 Gilead Calistoga Llc Forme polimorfe ale (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilchinazolin-4(3H)-onei
CN107262912B (zh) * 2012-03-30 2020-08-07 布莱阿姆青年大学 用于摩擦搅拌操作的过程控制的作用力调制
MX2014014831A (es) 2012-06-08 2015-02-12 Hoffmann La Roche Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer.
EP2970329A1 (en) * 2013-03-13 2016-01-20 F. Hoffmann-La Roche AG Process for making benzoxazepin compounds
JP6260967B2 (ja) * 2013-11-06 2018-01-17 国立大学法人京都大学 放射性ヨウ素標識化合物、及び、これを含む放射性医薬
CN111848643A (zh) 2015-07-02 2020-10-30 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
EP4585597A1 (en) 2015-07-02 2025-07-16 F. Hoffmann-La Roche AG Benzoxazepin oxazolidinone compounds and methods of use
EP3851441B1 (en) 2016-12-15 2023-06-28 F. Hoffmann-La Roche AG Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide
WO2018197653A1 (en) * 2017-04-28 2018-11-01 F. Hoffmann-La Roche Ag Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
JP2021532139A (ja) 2018-07-23 2021-11-25 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐｉ３ｋ阻害剤であるｇｄｃ−００７７による癌の治療方法
JP2022504388A (ja) 2018-10-08 2022-01-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｉ３ｋアルファ阻害剤およびメトホルミンを用いたがんの処置方法
TW202133857A (zh) 2019-12-03 2021-09-16 美商建南德克公司 用於乳癌治療之組合療法

Also Published As

Publication number Publication date
IL255200B (en) 2020-05-31
MX388533B (es) 2025-03-20
EP3567045B1 (en) 2022-01-12
KR20190100432A (ko) 2019-08-28
US20240199594A1 (en) 2024-06-20
EP4212536A1 (en) 2023-07-19
KR102014326B1 (ko) 2019-08-26
TWI601732B (zh) 2017-10-11
MY195002A (en) 2022-12-30
AU2016287463A1 (en) 2017-10-26
DK3317284T3 (da) 2020-01-13
US20210246129A1 (en) 2021-08-12
LT3317284T (lt) 2020-01-27
HUE046756T2 (hu) 2020-03-30
PT3317284T (pt) 2020-01-10
CA2982708C (en) 2023-10-03
JP7266630B2 (ja) 2023-04-28
UA121678C2 (uk) 2020-07-10
IL272277A (en) 2020-02-27
CL2017003436A1 (es) 2018-05-04
US10851091B2 (en) 2020-12-01
ES2908300T3 (es) 2022-04-28
TWI649326B (zh) 2019-02-01
US20250326745A1 (en) 2025-10-23
CN111909173A (zh) 2020-11-10
RU2018103454A3 (es) 2019-11-21
RU2730529C2 (ru) 2020-08-24
PL3317284T3 (pl) 2020-04-30
PL3567045T3 (pl) 2022-04-19
EP3567045A1 (en) 2019-11-13
US20190263793A1 (en) 2019-08-29
EP3778607A1 (en) 2021-02-17
ZA202500997B (en) 2025-10-29
PE20181021A1 (es) 2018-06-27
AU2016287463B2 (en) 2020-07-02
CA2982708A1 (en) 2017-01-05
US10112932B2 (en) 2018-10-30
FIC20253008I1 (fi) 2025-09-22
PH12017502425A1 (en) 2018-07-02
BR112017023121A2 (pt) 2018-07-10
PH12020551315A1 (en) 2021-07-05
MA54252A (fr) 2022-04-27
WO2017001645A1 (en) 2017-01-05
AU2020204418B2 (en) 2022-02-03
CN111909173B (zh) 2025-03-04
SI3317284T1 (sl) 2020-02-28
CN112062778B (zh) 2024-04-19
PE20211775A1 (es) 2021-09-08
SG10201913980SA (en) 2020-03-30
JP2021119144A (ja) 2021-08-12
EP3778607C0 (en) 2023-08-30
US9650393B2 (en) 2017-05-16
JP6523490B2 (ja) 2019-06-05
US20170015678A1 (en) 2017-01-19
CN107873032A (zh) 2018-04-03
EP4585597A1 (en) 2025-07-16
RS59740B1 (sr) 2020-02-28
TW201712020A (zh) 2017-04-01
NL301344I2 (nl) 2025-11-10
EP4212536B1 (en) 2025-02-19
TW202108592A (zh) 2021-03-01
KR20180006460A (ko) 2018-01-17
US20250197386A1 (en) 2025-06-19
CN112062778A (zh) 2020-12-11
IL272277B (en) 2021-01-31
FR25C1039I1 (fr) 2025-11-21
JP2018519307A (ja) 2018-07-19
MX372624B (es) 2020-05-07
MX2017016344A (es) 2018-05-02
US20180127404A1 (en) 2018-05-10
EP3317284A1 (en) 2018-05-09
EP3317284B1 (en) 2019-10-30
ES2764497T3 (es) 2020-06-03
HRP20192349T1 (hr) 2020-03-20
HK1253003A1 (zh) 2019-06-06
EP4212536C0 (en) 2025-02-19
US11760753B2 (en) 2023-09-19
LTPA2025536I1 (es) 2025-10-10
IL277774A (en) 2020-11-30
HUS2500040I1 (hu) 2025-10-28
JP2019178135A (ja) 2019-10-17
IL255200A0 (en) 2017-12-31
KR102306071B1 (ko) 2021-10-01
ZA201808370B (en) 2023-03-29
CN112047960B (zh) 2024-08-02
NZ775526A (en) 2024-05-31
MA49861A (fr) 2021-05-05
US20170210733A1 (en) 2017-07-27
CN107873032B (zh) 2020-07-17
CR20170563A (es) 2018-02-20
NO2025044I1 (no) 2025-09-23
NZ736222A (en) 2024-05-31
JP2023103242A (ja) 2023-07-26
RU2018103454A (ru) 2019-08-05
TW201815798A (zh) 2018-05-01
JP6880101B2 (ja) 2021-06-02
MX2020003415A (es) 2021-12-07
EP3778607B1 (en) 2023-08-30
AU2020204418A1 (en) 2020-07-23
TWI698440B (zh) 2020-07-11
TW201936612A (zh) 2019-09-16
CN112047960A (zh) 2020-12-08
CO2017011038A2 (es) 2018-02-09
MA42295B1 (fr) 2020-02-28

Similar Documents

Publication Publication Date Title
AR105238A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
AR095039A1 (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
CR20210032A (es) Compuestos
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
MX380394B (es) Compuesto novedoso de bifenilo o una sal del mismo.
UY36314A (es) NUEVOS COMPUESTOS ANTAGONISTAS DE INTEGRINA avß6.
CU20170057A7 (es) Derivados de feniltriazol sustituido con hidroxialquilo
AR111304A1 (es) Métodos para sintetizar un inhibidor de mcl-1
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
NZ725165A (en) Analogues of 4h-pyrazolo[1,5-α]benzimidazole compound as parp inhibitors
AR103680A1 (es) Inhibidores selectivos de bace1
AR098870A1 (es) Formas polimorficas de una sal de clorhidrato de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolin-4(3h)-ona
MA39956A (fr) Analogues du benzomorphane et leur utilisation
MX2019007339A (es) Compuestos de pirazolopirimidina y metodos de uso de los mismos.
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
MA44781B1 (fr) Composé hétérocyclique condensé
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
DOP2018000042A (es) Antagonistas del receptor de cgrp
JOP20200030A1 (ar) مركب خماسي الحلقة
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
AR106876A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
AR107163A1 (es) Inhibidores de quinasa

Legal Events

Date Code Title Description
FG Grant, registration